ABBV News
2 R40 articles on AbbVie Inc. (ABBV). Latest, Sep 18, 2026: Medicaid's MFN Rebate Stacks on a 62-77% Discount. Mississippi Already Beats It.
R40 Coverage
Medicaid's MFN Rebate Stacks on a 62-77% Discount. Mississippi Already Beats It.
The White House will say all 50 states get most-favored-nation Medicaid pricing. It stacks on existing rebates, and a July study says Mississippi wins now.
AbbVie Q2 2026: Skyrizi and Rinvoq Keep Compounding — Stock Falls on a Narrow EPS Miss
AbbVie beat revenue estimates as Skyrizi and Rinvoq grew over 24% each, but adjusted EPS missed by 6 cents and full-year guidance came down, sending shares down nearly 5%. We break down the immunology growth story against the near-term guidance drag.
February 2026
AbbVie Posts Double Beat for Q4
Q4 EPS $2.71 vs $2.65 est, revenue $16.62B vs $16.42B est; FY26 EPS guidance $14.37-$14.57 vs $14.24 est, signaling robust earnings growth.
AbbVie All In on Obesity
AbbVie signals heavy obesity focus without explicit statement; expected to compete with Novo Nordisk, Merck, Bristol-Myers Squibb, emphasizing efficacy over oral vs. subcutaneous.
January 2026
AbbVie at JPM is All In on Obesity
AbbVie expresses enthusiasm for phase 1-2 obesity assets; anticipates big showdown with competitors like Novo Nordisk, Merck, and Lilly in weeks, not months.
Biopharma Sentiment Just Snapped Higher
Biopharma sentiment surged with BPSI index jumping 78 to 90; aligns with public market price action and deal flow, expecting continued M&A and IPO activity into summer.